RxDoctor Payments Data

Jemetta Harvey

Nurse Practitioner · Beech Island, SCNPI 1962757302

Payments from drug & device makers

$1,334in general payments, 2019–2025

Across 50 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$264
  • AbbVie$186
  • AstraZeneca$162
  • Exact Sciences$158
  • Novo Nordisk$112
  • Neurocrine Biosciences, Inc.$111
  • plus $341 from 9 others

What the payments were for

  • Food & beverage$1,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,334 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$508
Medicare patients
29
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$192,142
FarxigaDapagliflozin Propanediol113$158,623
MounjaroTirzepatide44$118,741
RybelsusSemaglutide42$107,015
Xigduo XrDapaglifloz Propaned/Metformin64$96,724
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$86,348
EliquisApixaban50$75,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$73,866
TrulicityDulaglutide25$65,455
JardianceEmpagliflozin30$34,031
MyrbetriqMirabegron23$26,714
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$26,428
Combivent RespimatIpratropium/Albuterol Sulfate21$24,878
GlyxambiEmpagliflozin/Linagliptin13$23,077
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$20,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$112$299,157116 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$162$263,503201 claims
Lilly USA, LLCMounjaro, Trulicity$264$184,19669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Beech Island

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →